Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitié MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O; M72 Study Group. Leroux-Roels I, et al. Among authors: ledent e. Vaccine. 2013 Apr 19;31(17):2196-206. doi: 10.1016/j.vaccine.2012.05.035. Epub 2012 May 27. Vaccine. 2013. PMID: 22643213 Clinical Trial.
Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study.
Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Chlibek R, et al. Among authors: ledent e. Vaccine. 2014 Mar 26;32(15):1745-53. doi: 10.1016/j.vaccine.2014.01.019. Epub 2014 Feb 6. Vaccine. 2014. PMID: 24508036 Clinical Trial.
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, Normand-Bayle M, Oostvogels L, Da Silva FT, Vassilev V, Vinals C, Brecx A. Lecrenier N, et al. Among authors: ledent ey. Expert Rev Vaccines. 2018 Jul;17(7):619-634. doi: 10.1080/14760584.2018.1495565. Epub 2018 Jul 20. Expert Rev Vaccines. 2018. PMID: 30028651 Review.
ADVANCE system testing: Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling.
Bollaerts K, Ledent E, de Smedt T, Weibel D, Emborg HD, Danieli G, Duarte-Salles T, Huerta-Alvarez C, Martín-Merino E, Picelli G, Tramontan L, Sturkenboom M, Bauchau V. Bollaerts K, et al. Among authors: ledent e. Vaccine. 2020 Dec 22;38 Suppl 2:B65-B75. doi: 10.1016/j.vaccine.2019.09.034. Epub 2019 Oct 31. Vaccine. 2020. PMID: 31677947 Free article.
Attributes influencing parental decision-making to receive the Tdap vaccine to reduce the risk of pertussis transmission to their newborn - outcome of a cross-sectional conjoint experiment in Spain and Italy.
Ledent E, Gabutti G, de Bekker-Grob EW, Alcázar Zambrano JL, Campins Martí M, Del Hierro Gurruchaga MT, Fernández Cruz MJ, Ferrera G, Fortunato F, Torchio P, Zoppi G, Agboton C, Kandeil W, Marchetti F. Ledent E, et al. Hum Vaccin Immunother. 2019;15(5):1080-1091. doi: 10.1080/21645515.2019.1571890. Epub 2019 Apr 15. Hum Vaccin Immunother. 2019. PMID: 30735474 Free PMC article.
22 results